Talk:Amphotericin B

From Wikipedia, the free encyclopedia

	Amphotericin B is part of WikiProject Pharmacology, a project to improve all Pharmacology-related articles. If you would like to help improve this and other pharmacology articles, please join the project. All interested editors are welcome.
B	This article has been rated as B-Class on the quality scale.
High	This article has been rated as high-importance for this Project's importance scale.

Research work is going on AmphotericinB with concepts from Nanotechnology for early identification or AIDS

Well, provide a reference and stick it in the article! I fail to understand how an antifungal could be of any use in detecting viral particles, but I hope you can enlighten us. JFW | T@lk 13:41, 27 May 2005 (UTC)

[edit] Creutzfeldt-Jakob Disease

Sorry that I added this to the uses section, I was just refering to information found in here. The quote is "Both amphotericin B and doxorubicin have been investigated as potentially effective against CJD, but as yet there is no strong evidence that either drug is effective..."

Also, searches of this drug with CJD show that testing has been done with these. I didn't see references for anything else on this page and didn't want to add a references section just for this one comment.

I do not profess to be a doctor. I just saw that info on the CJD article had AmphotericinB in it and decided to add it here. --Thingy1 (talk) 18:08, 28 March 2008 (UTC)

[edit] amphotericin-b CAPSULES

NON-TOXIC form of amphotericin-b

[edit] New delivery system

This was added:

Researchers (Wasan KM et al.) at the University of British Columbia (Canada) discovered new drug delivery system for Amphotericin B (AMB), bypassing notable renal toxicity associated with currently available intravenous AMB formulation. A clinical study of the drug delivery system, involving 50-100 patients, is planned for later this year. Newer oral AMB preparation will provide more effective, less toxic and cheaper alternative to intravenous AMB, as per press release submitted on 5-March-2006.

This needs rewriting. What is the delivery system? Why is it different from AmBisome? What benefits are expected? Why do we need to mention a system that hasn't even finished its trials? JFW | T@lk 22:35, 5 March 2007 (UTC)

Yes, I agree, this is too vague. Also, instead of citing press releases, which are about as useful and unskewed as Pravda or Faux News, we would need the original reference for evaluation.

Instead of listing all commercial preparations, it would be more useful to emphasize the common principle of the lipid/liposome preparations, i.e. the reduction of the free concentration of amphotericin B, which prevents it from accumulation at toxic concentrations in human cell membranes. The fungal cell membranes, since they contain ergosterol, bind amphotericin more avidly and will extract the amphotericin from the liposomal carriers over time.

Re the other 'news' on potassium efflux not always leading to cell death: That is old stuff; cell killing is dose-dependent. I don't think it has been shown that the concentrations that are reached inside the fungal cell membranes in vivo are sublethal. —Preceding unsigned comment added by 129.97.47.157 (talk) 23:55, 18 February 2008 (UTC)